Biofrontera (BFRI)
Provides AMELUZ and RhodoLED photodynamic therapy for dermatology practices.
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q2 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Reports Q2 Loss, Beats Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.57 per share a year ago.
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
WOBURN, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the quarter ended June 30, 2026.
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz® (aminolevulinic acid hydrochloride) Gel, 10% with the BF-RhodoLED® lamp for photodynamic therapy (PDT) of actinic keratosis, today announced that it will report financial results for the second quarter ended June 30, 2026 before the market opens on Thursday, August 13, 2026.
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
Biofrontera Inc. (BFRI) Shareholder/Analyst Call Prepared Remarks Transcript
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass. , May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.
Biofrontera Inc. (BFRI) Reports Q1 Loss, Beats Revenue Estimates
Biofrontera Inc. (BFRI) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.47 per share a year ago.
Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update.
Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness Day This social media–driven initiative invites people to wear a hat, share a photo, and help raise awareness of AK and the importance of comprehensive sun protection Actinic Keratosis affects an estimated 58 million Americans and, if left untreated, can develop into squamous cell carcinoma1 Woburn, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the return of the Hats On Campaign for its second consecutive year.
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
WOBURN, Mass. , May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months ended March 31, 2026 after the close of the U.
Biofrontera Inc. to Report First Quarter 2026 Financial Results and Host a Conference Call on May 14, 2026
WOBURN, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Thursday, May 14, 2026. The Company will host a conference call on Thursday, May 14, 2026 at 11:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions. Conference Call and Webcast Information
Biofrontera Q4 Earnings Call Highlights
Biofrontera (NASDAQ: BFRI) reported record revenue for both the fourth quarter and full year 2025, driven by higher Ameluz photodynamic therapy (PDT) demand and a major change to its U.S. rights and supply economics following an amended arrangement with former parent Biofrontera AG. Record revenue and a profitable fourth quarter CEO Hermann Luebbert said fiscal 2025
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q4 2025 Earnings Call Transcript
Biofrontera Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Conference call will be held today, Thursday, March 19 at 10:00 am ET Woburn, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024.
Biofrontera Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Host a Conference Call on March 19, 2026
WOBURN, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), announces it will report financial results for the three months and full year ended December 31, 2025 after the close of the U.S. financial markets on Thursday, March 19, 2026. The Company will host a conference call on Thursday, March 19, 2026 at 10:00 a.m. Eastern Time to discuss those results, provide a business update and answer questions.
Biofrontera Inc. (BFRI) Upgraded to Buy: Here's Why
Biofrontera Inc. (BFRI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
• Phase 2b study demonstrated greater reductions in inflammatory acne lesions with Ameluz ® PDT versus vehicle
U.S. Patent Office Issues Final Written Decision Finding All Challenged Claims of Sun Pharma's Patent 11,697,028 To Be Unpatentable
WOBURN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization and development of photodynamic therapy (“PDT”), today announced that on February 23, 2026, the U.S. Patent Trial and Appeal Board (the “Board”) issued a Final Written Decision finding all challenged claims of Sun Pharmaceutical Industries, Inc.'s U.S. Patent No. 11,697,028 (the “'028 Patent”) to be unpatentable.
Contrasting Biofrontera (NASDAQ:BFRI) & RenovaCare (OTCMKTS:RCAR)
RenovaCare (OTCMKTS:RCAR - Get Free Report) and Biofrontera (NASDAQ: BFRI - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability. Insider and Institutional Ownership 10.1% of Biofrontera shares are owned